Is the IRA a Headwind for Gene Therapy?

Despite positive individual outcomes for new drugs, the industry as a whole seems to be in a negative sentiment spiral. The IRA passed suggests that the seeming omnipotence or like imperviousness of the drug industry to lobby Congress is maybe a harbinger of more to come. You know, we're going to see whether or not Bluebird can sell its gene therapy for beta thalassemia.